• Collplant Biotechnologies Ltd CLGN.OQ reported a quarterly adjusted loss of 28 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -37 cents. The lone analyst forecast for the quarter was for a loss of 14 cents per share.

• Revenue fell 28.1% to $179.00 thousand from a year ago; analysts expected $2.54 million.

• Collplant Biotechnologies Ltd's reported EPS for the quarter was a loss of 28 cents​.

• The company reported a quarterly loss of $3.35 million.

• Collplant Biotechnologies Ltd shares had risen by 81.2% this quarter and lost 31.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 366.7% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• Wall Street's median 12-month price target for Collplant Biotechnologies Ltd is $12.00, about 79.5% above its last closing price of $2.47

This summary was machine generated from LSEG data August 20 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)